It was found that when taking tadalafil, the average daily frequency and duration of Raynaud's episodes experienced by patients were less: 2.23 episodes versus 3.36, and 31.5 minutes versus 53.9 minutes respectively.
All the 24 ulcers present at the start of treatment healed while on tadalfil, compared to only three out of 13 while on placebo. One new fingertip ulcer was reported while taking tadalafil; 13 new ulcers were reported while on placebo.
The researchers also said that patients' overall assessments, as well as physicians' overall assessments of Raynaud's phenomenon, significantly improved while patients were taking tadalafil, without any serious side effects.
"This research has proven the excellent efficacy of tadalafil in the treatment of the Raynaud's phenomenon and ischemic ulcers secondary to it. This study also generates a new hope in the treatment of scleroderma, which is currently incurable.
It has to be seen in further studies whether tadalafil can improve survival in scleroderma patients," says Padmanabha Shenoy.
The findings of the study were presented at the American College of Rheumatology Annual Scientific Meeting in San Francisco, California.
Source-ANI
SRM/SK